PepsRadar
⌕ Search✧ Ask
Content updated · how dates work
The claim
“'GLP-4' Metatrutide is a new four-receptor weight-loss peptide, the next step after 'GLP-3' retatrutide.”
Verdict: False
There is no drug called metatrutide in PubMed, ClinicalTrials.gov or FDA records, and 'GLP-4' is not a hormone or a drug class. One seller's own strength table lists its 'GLP-4 Metatrutide' vial as retatrutide plus a smaller amount of PEG-MGF: two existing compounds mixed in one vial, not a new molecule. Neither part is approved, and the mixture has never been studied.
No. 'GLP-4' is seller numbering that extends the informal 'GLP-1, GLP-2, GLP-3' codes, not a medical term. The product sold as 'GLP-4 Metatrutide' is described by at least one seller as retatrutide plus PEG-MGF in one vial. Retatrutide is an investigational drug with large phase 3 trials, but those trials used Lilly's manufactured drug, not research vials, and PEG-MGF has no human studies at all. No study has tested the two together.
2:49Video overview · 2:49
How the triple-hormone drug is thought to work, what the phase 2 and phase 3 trials found, the side effects, the trials still under way, its legal status, and why vials sold online are not the drug tested in those trials.
Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗
Online peptide shops number GLP-1 products by how many hormone receptors the drug is said to act on: 'GLP-1' for semaglutide (one receptor), 'GLP-2' for tirzepatide (two) and 'GLP-3' for retatrutide (three). These are seller codes, not names used by drug makers, regulators or medical journals. The numbering is also confusing because GLP-2 is the name of a real, unrelated gut hormone.
'GLP-4' extends the same pattern to suggest a fourth step. When we checked on October 15, 2026, PubMed had no record of a drug called metatrutide, ClinicalTrials.gov had no registered study of it, and the only 'glp-4' in PubMed is a gene used in laboratory research on the roundworm C. elegans. No human hormone called GLP-4 exists.
Sources: ncbi.nlm.nih.gov · clinicaltrials.gov · PubMed 36575738
One shop that sells 'GLP-4 Metatrutide' publishes a strength table on its product pages. For this product it lists 'GLP-3 RT' (the shop's code for retatrutide) and PEG-MGF together in the same vial, with more retatrutide than PEG-MGF. Other listings describe the product as acting on GLP-1, GIP, glucagon and 'MGF-associated' pathways, which matches a mixture of the two rather than a single new molecule.
A label is the seller's description, not proof of contents. Without independent testing of a specific batch, nobody can say what a given vial actually holds or how much of each part is present.
Sources: disguisedalpha.com
Retatrutide is a real investigational drug from Eli Lilly that acts on the GIP, GLP-1 and glucagon receptors. In the TRIUMPH-2 phase 3 trial, 1,152 adults with obesity and type 2 diabetes lost more weight on retatrutide than on placebo, with more gastrointestinal side effects. It is not approved, and the FDA has warned sellers of research-labeled retatrutide. Results from Lilly's trials cannot be assumed for vials sold online under the same name.
PEG-MGF is a modified version of a fragment called mechano growth factor. It has never been tested in people. When scientists at two drug companies tested the mechano growth factor peptide in 2014, it had no apparent effect on mouse or human muscle cells. Mechano growth factors are banned in sport by the World Anti-Doping Agency.
Sources: PubMed 42810372 · fda.gov · PubMed 24253050 · wada-ama.org
No study has tested retatrutide and PEG-MGF together, so there is no evidence about whether the mixture works, how the two interact, or whether it is safe. We also cannot rule out that other sellers use the name 'metatrutide' for a different mixture. Real multi-receptor weight-loss drugs are in development, such as retatrutide and UBT251, but they are tested as single, defined molecules in registered trials, not sold under seller numbers.
Sources: PubMed 42810372
Retatrutide profile → · Retatrutide risks & interactions → · MGF profile → · MGF risks & interactions → · PEG-MGF profile → · PEG-MGF risks & interactions →
These are original summaries of published research, written with AI assistance from the cited studies. Each reference was matched to its PubMed record by title, year and journal; the summaries themselves have not been independently checked line by line against the full papers, so errors are possible (corrections). They are not medical advice and have not been reviewed by a clinician. All claim checks · Editorial standards
See something wrong on this page? Report a mistake · Corrections